State Bank of India (SBI) is considering joining a group of global lenders to provide funding for Sun Pharmaceutical Industries Ltd.’s planned overseas acquisition in the United States, according to people familiar with the matter. The financing being discussed is about $1 billion for SBI, as part of a larger funding effort totaling around $12 billion for the deal. The reports indicate that SBI’s participation would be coordinated with other international lenders rather than through a standalone arrangement. Details on the acquisition target, timing, deal structure, and final terms were not provided in the cited accounts. The information is described as coming from individuals familiar with the matter, suggesting discussions are at least partly in progress. Both outlets frame the development as a planned bank participation in the credit package rather than a final, publicly confirmed agreement. No official statement from SBI or Sun Pharma is reflected in the provided excerpts.